Wachira Joins US Pharmacopeia
Catherine Wachira has joined The US Pharmacopeia (USP, www.usp.org), as director of the Drug Quality and Information (DQI) program.
Catherine Wachira has joined The US Pharmacopeia (USP, www.usp.org), as director of the Drug Quality and Information (DQI) program. USP’s DQI program provides assistance in drug quality assurance, develops and disseminates drug and therapeutic information, trains laboratory staff, and provides scientific evidence for healthcare decision-making in developing countries. Wachira previously served as director of clinical research for Callisto Pharmaceuticals.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
